Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis.

Liver metastasis is a fatal step in the progression of colorectal cancer (CRC); however, the epigenetic evolution of this process is largely unknown. To decipher the epigenetic alterations during the development of liver metastasis, the DNA methylation status of 12 genes, including 5 classical CpG island methylator phenotype (CIMP) markers, was analyzed in 62 liver metastases and in 78 primary CRCs (53 stage I-III; 25 stage IV). Genome-wide methylation analysis was also performed in stage I-III CRCs and in paired primary and liver metastatic cancers. Methylation frequencies of MGMT and TIMP3 increased progressively from stage I-III CRCs to liver metastasis (P = 0.043 and P = 0.028, respectively). The CIMP-positive cases showed significantly earlier recurrence of disease than did CIMP-negative cases with liver metastasis (P = 0.030), whereas no such difference was found in stage I-III CRCs. Genome-wide analysis revealed that more genes were methylated in stage I-III CRCs than in paired stage IV samples (P = 0.008). Hierarchical cluster analysis showed that stage I-III CRCs and stage IV CRCs were clustered into two distinct subgroups, whereas most paired primary and metastatic cancers showed similar methylation profiles. This analysis revealed distinct methylation profiles between stage I-III CRCs and stage IV CRCs, which may reflect differences in epigenetic evolution during progression of the disease. In addition, most methylation status in stage IV CRCs seems to be established before metastasis.

[1]  N. Gusani,et al.  Survival Outcomes of Patients with Colorectal Liver Metastases Following Hepatic Resection or Ablation in the Era of Effective Chemotherapy , 2009, Annals of Surgical Oncology.

[2]  M. Masuda,et al.  Quantitative measurement of venous invasion of colorectal cancer with metachronous liver metastasis , 2009, Histopathology.

[3]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[4]  R. Hynes.  Metastatic Potential Generic Predisposition of the Primary Tumor or Rare, Metastatic Variants—Or Both? , 2003, Cell.

[5]  Y. Bai,et al.  Clinicopathologic significance of BAG1 and TIMP3 expression in colon carcinoma. , 2007, World journal of gastroenterology.

[6]  M. Roncalli,et al.  Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer , 2006, British Journal of Cancer.

[7]  Gary L Rosner,et al.  Tumour vasculature: On the verge of collapse , 2005, Nature Reviews Cancer.

[8]  R. Palmqvist,et al.  The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status , 2010, Clinical Cancer Research.

[9]  N. Koshikawa,et al.  Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model , 2003, Oncogene.

[10]  P. Laurent-Puig,et al.  Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. , 2008, Cancer research.

[11]  V. Bramwell,et al.  The functional and clinical roles of osteopontin in cancer and metastasis. , 2001, Current molecular medicine.

[12]  Minoru Toyota,et al.  Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer , 2007, Proceedings of the National Academy of Sciences.

[13]  Tsung-Teh Wu,et al.  Epigenetic alterations in neuroendocrine tumors: methylation of RAS-association domain family 1, isoform A and p16 genes are associated with metastasis , 2005, Modern Pathology.

[14]  Paula D. Bos,et al.  Metastasis: from dissemination to organ-specific colonization , 2009, Nature Reviews Cancer.

[15]  G. Casey,et al.  Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer , 2009, The British journal of surgery.

[16]  R. Wolff,et al.  Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. , 2005, Cancer research.

[17]  D. Threadgill.  Metastatic potential as a heritable trait , 2005, Nature Genetics.

[18]  T. Sun,et al.  Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. , 1994, The Journal of biological chemistry.

[19]  A. Rowan,et al.  O6-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions , 2005, Gut.

[20]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[21]  M. Loda,et al.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies , 2006, Gut.

[22]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R. Ward,et al.  Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  B. Iacopetta,et al.  CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  J. Herman,et al.  Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. , 2000, Cancer research.

[26]  Lanlan Shen,et al.  Characteristic methylation profile in CpG island methylator phenotype‐negative distal colorectal cancers , 2010, International journal of cancer.

[27]  S. Baba,et al.  Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer. , 2008, Urology.

[28]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Gray,et al.  Cancer: Genomics of metastasis , 2010, Nature.

[30]  Richard Stang,et al.  Resection of colorectal liver metastases , 1997, Journal of Gastrointestinal Surgery.

[31]  J. Issa,et al.  Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. , 2008, Carcinogenesis.

[32]  J. Herman,et al.  K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W. Chapman,et al.  CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer , 2006, Genes, chromosomes & cancer.

[34]  I. Fidler,et al.  Metastasis results from preexisting variant cells within a malignant tumor. , 1977, Science.

[35]  Joe W Gray,et al.  Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. , 2003, Cancer cell.

[36]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[37]  H. Aburatani,et al.  Three DNA Methylation Epigenotypes in Human Colorectal Cancer , 2009, Clinical Cancer Research.

[38]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[39]  Charles Swanton,et al.  Genetic prognostic and predictive markers in colorectal cancer , 2009, Nature Reviews Cancer.

[40]  P. Malfertheiner,et al.  Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. , 2005, Carcinogenesis.

[41]  Y. Nagashima,et al.  Expression of matrilysin in vascular endothelial cells adjacent to matrilysin‐producing tumors , 1997, International journal of cancer.

[42]  P. Catalano,et al.  Association between DNA Methylation and Shortened Survival in Patients with Advanced Colorectal Cancer Treated with 5-Fluorouracil–Based Chemotherapy , 2007, Clinical Cancer Research.

[43]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[44]  W. Loo,et al.  DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[45]  T. Pawlik,et al.  Current management of colorectal hepatic metastasis , 2009, Expert review of gastroenterology & hepatology.

[46]  Shuji Ogino,et al.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer , 2008, Gut.

[47]  Peter A. Jones,et al.  The Role of DNA Methylation in Mammalian Epigenetics , 2001, Science.

[48]  A. Khabir,et al.  Inactivation of RASSF1A, RARβ2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma , 2009 .

[49]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[50]  S. Ogino,et al.  PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. , 2008, Neoplasia.

[51]  C. Boland,et al.  Somatic evolution of cancer cells. , 2005, Seminars in cancer biology.

[52]  N. Bird,et al.  Biology of colorectal liver metastases: A review , 2006, Journal of surgical oncology.

[53]  L. Sobin,et al.  The TNM system: Our language for cancer care , 2002, Journal of surgical oncology.

[54]  Hiroshi Nakayama,et al.  Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. , 2002, Cancer letters.

[55]  N. Cho,et al.  Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers , 2009, Virchows Archiv.

[56]  J. Forster,et al.  A study of prognostic factors for hepatic resection for colorectal metastases. , 1997, American journal of surgery.

[57]  G. Weber.  Molecular mechanisms of metastasis. , 2008, Cancer letters.

[58]  Li Zhang,et al.  Genome-Wide Profiling of DNA Methylation Reveals a Class of Normally Methylated CpG Island Promoters , 2007, PLoS genetics.

[59]  J. Issa.  CpG island methylator phenotype in cancer , 2004, Nature Reviews Cancer.

[60]  M. Toyota,et al.  Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. , 2009, Cancer research.

[61]  J. Herman,et al.  Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. , 2001, Cancer research.

[62]  A. Jimeno,et al.  Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma , 2008, Cancer biology & therapy.